Euro-Med Laboratories Philippines (PHS:EURO) Long-Term Debt: ₱857 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHS:EURO Euro-Med Laboratories Philippines Inc PHS:EURO
83 GF Score
Price ₱1.10
GF Value ₱1.03
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Euro-Med Laboratories Philippines Long-Term Debt?

Euro-Med Laboratories Philippines PHS:EURO 83 Long-Term Debt is ₱857 Mil as of Mar. 2026. GuruFocus rates PHS:EURO with a GF Score™ of 83/100 and a GF Value™ of ₱1.03 (Fairly Valued). The stock has 7 warning signs investors should review.

Euro-Med Laboratories Philippines's Long-Term Debt for the quarter that ended in Mar. 2026 was ₱857 Mil.

Euro-Med Laboratories Philippines's quarterly Long-Term Debt increased from Sep. 2025 (₱805 Mil) to Dec. 2025 (₱857 Mil) but then stayed the same from Dec. 2025 (₱857 Mil) to Mar. 2026 (₱857 Mil).

Euro-Med Laboratories Philippines's annual Long-Term Debt increased from Dec. 2023 (₱667 Mil) to Dec. 2024 (₱774 Mil) and increased from Dec. 2024 (₱774 Mil) to Dec. 2025 (₱857 Mil).

Euro-Med Laboratories Philippines  (PHS:EURO) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Euro-Med Laboratories Philippines Long-Term Debt Related Terms

Euro-Med Laboratories Philippines Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Euro-Med Laboratories Philippines's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Euro-Med Laboratories Philippines Long-Term Debt Chart

Euro-Med Laboratories Philippines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 788.75 663.62 666.91 774.25 857.30

Euro-Med Laboratories Philippines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 771.24 768.23 804.89 857.30 857.30
PHS:EURO
83GF Score
Euro-Med Laboratories Philippines Inc PHS:EURO
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₱857 Mil mean?
Euro-Med Laboratories Philippines (PHS:EURO) has a Long-Term Debt of ₱857 Mil as of Mar. 2026.
Is Euro-Med Laboratories Philippines' Long-Term Debt too high?
Euro-Med Laboratories Philippines' current Long-Term Debt is ₱857 Mil. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' Long-Term Debt compare to ZTS and UTHR?
Euro-Med Laboratories Philippines' Long-Term Debt of ₱857 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Euro-Med Laboratories Philippines's current Long-Term Debt is ₱857 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.03, compared to a current price of ₱1.10 — trading 6.8% above its estimated fair value. The current Long-Term Debt is ₱857 Mil. Euro-Med Laboratories Philippines' overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current Long-Term Debt is ₱857 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?

Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be overvalued. The current stock price of ₱1.10 is trading 6.8% above its estimated GF Value™ of ₱1.03. GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.

Key valuation signals for PHS:EURO:

  • Long-Term Debt: ₱857 Mil
  • GF Value™: ₱1.03 vs. price of ₱1.10 (6.8% above fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Euro-Med Laboratories Philippines Business Description

Address San Marcelino Street, United Nations Avenue corner, PPL Building, 2nd floor, Manila, PHL, 1000
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
83GF Score

Get the complete analysis for PHS:EURO

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₱1.10
Price
₱1.03
GF Value